Drug eluting devices for critically ill patients: Can we apply lessons learned from the treatment of peripheral artery disease?

Advanced Drug Delivery Reviews

Volumn 77, Issue , 2014, Pages 32-39

  Werner, Martin ^a   Scheinert, Dierk ^b  

^a HANUSCH HOSPITAL   (Austria)

^b Center for Vascular Medicine   (Germany)

Author keywords

Critical limb ischemia; Drug eluting balloons; Drug eluting stents; Peripheral artery disease; Peripheral catheterization; Restenosis

Indexed keywords

ARTIFICIAL ORGANS; BALLOONS; DIAGNOSIS; DRUG DELIVERY; STENTS; TISSUE REGENERATION;

CRITICAL LIMB ISCHEMIA; DRUG-ELUTING STENTS; PERIPHERAL ARTERY DISEASE; PERIPHERAL CATHETERIZATION; RESTENOSIS;

DISEASES;

EVEROLIMUS; PACLITAXEL; RAPAMYCIN;

ANATOMICAL VARIATION; BARE METAL STENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CRITICAL LIMB ISCHEMIA; CRITICALLY ILL PATIENT; DRUG COATING; DRUG ELUTING BALLOON; DRUG ELUTING STENT; HUMAN; IMPLANT; IN-STENT RESTENOSIS; LIMB SALVAGE; MANAGED CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR PATENCY; WOUND HEALING; CORONARY RESTENOSIS; CRITICAL ILLNESS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES;

ANGIOPLASTY, BALLOON; CORONARY RESTENOSIS; CRITICAL ILLNESS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; VASCULAR PATENCY;

EID: 84919463614     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.07.005     Document Type: Review

References (49)

1. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. Jan 2007, 45(Suppl. S):S5-S67.
2. Novo S., Coppola G., Milio G. Critical limb ischemia: definition and natural history. Curr. Drug Targets Cardiovasc. Haematol. Disord. Sep 2004, 4(3):219-225.
3. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J. Am. Coll. Cardiol. Mar 21 2006, 47(6):1239-1312.
4. Bertomeu V., Morillas P., Gonzalez-Juanatey J.R., et al. Prevalence and prognostic influence of peripheral arterial disease in patients>or=40years old admitted into hospital following an acute coronary event. Eur. J. Vasc. Endovasc. Surg. Aug 2008, 36(2):189-196.
5. Schillinger M., Minar E. Percutaneous treatment of peripheral artery disease: novel techniques. Circulation Nov 13 2012, 126(20):2433-2440.
6. Gruntzig A., Hopff H. Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique) (author's transl). Dtsch. Med. Wochenschr. Dec 6 1974, 99(49):2502-2510. (2511).
7. Gruntzig A.R., Senning A., Siegenthaler W.E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. Jul 12 1979, 301(2):61-68.
8. Schwartz R.S., Henry T.D. Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. 2002, 3(Suppl. 5):S4-S9.
9. Machan L. Clinical experience and applications of drug-eluting stents in the noncoronary vasculature, bile duct and esophagus. Adv. Drug Deliv. Rev. Jun 3 2006, 58(3):447-462.
10. Schillinger M., Sabeti S., Loewe C., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N. Engl. J. Med. May 4 2006, 354(18):1879-1888.
11. Krankenberg H., Schluter M., Steinkamp H.J., et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10cm in length: the femoral artery stenting trial (FAST). Circulation Jul 17 2007, 116(3):285-292.
12. Criqui M.H., Denenberg J.O., Langer R.D., Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc. Med. 1997, 2(3):221-226.
13. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. Jul 2012, 33(13):1635-1701.
14. Rollins K.E., Jackson D., Coughlin P.A. Meta-analysis of contemporary short- and long-term mortality rates in patients diagnosed with critical leg ischaemia. Br. J. Surg. Jul 2013, 100(8):1002-1008.
15. Adam D.J., Beard J.D., Cleveland T., et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet Dec 3 2005, 366(9501):1925-1934.
16. Heuser R.R., Henry M. Textbook of Peripheral Vascular Interventions 2008, Informa Healthcare, London Boca Raton, FL, (Distributed in North and South America by Taylor & Francis). 2nd ed.
17. Scheinert D., Scheinert S., Sax J., et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J. Am. Coll. Cardiol. Jan 18 2005, 45(2):312-315.
18. Schmidt A., Ulrich M., Winkler B., et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter. Cardiovasc. Interv. Dec 1 2010, 76(7):1047-1054.
19. Bauters C., Isner J.M. The biology of restenosis. Prog. Cardiovasc. Dis. Sep-Oct 1997, 40(2):107-116.
20. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. Dec 2005, 17(6):596-603.
21. Axel D.I., Kunert W., Goggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation Jul 15 1997, 96(2):636-645.
22. Gertz Z.M., Wilensky R.L. Local drug delivery for treatment of coronary and peripheral artery disease. Cardiovasc. Ther. Dec 2011, 29(6):e54-e66.
23. Laird J.R., Katzen B.T., Scheinert D., et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ. Cardiovasc. Interv. Jun 1 2010, 3(3):267-276.
24. Dorros G., Jaff M.R., Dorros A.M., Mathiak L.M., He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation Oct 23 2001, 104(17):2057-2062.
25. Feiring A.J., Wesolowski A.A., Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J. Am. Coll. Cardiol. Dec 21 2004, 44(12):2307-2314.
26. Scheinert D., Ulrich M., Scheinert S., Sax J., Braunlich S., Biamino G. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. EuroIntervention Aug 2006, 2(2):169-174.
27. Gasper W.J., Runge S.J., Owens C.D. Management of infrapopliteal peripheral arterial occlusive disease. Curr. Treat Options Cardiovasc. Med. Apr 2012, 14(2):136-148.
28. Scheinert D., Katsanos K., Zeller T., et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J. Am. Coll. Cardiol. Dec 4 2012, 60(22):2290-2295.
29. Rastan A., Tepe G., Krankenberg H., et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur. Heart J. Sep 2011, 32(18):2274-2281.
30. Bosiers M., Scheinert D., Peeters P., et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J. Vasc. Surg. Feb 2012, 55(2):390-398.
31. Feiring A.J., Krahn M., Nelson L., Wesolowski A., Eastwood D., Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (preventing amputations using drug eluting stents) trial. J. Am. Coll. Cardiol. April 13 2010, 55(15):1580-1589.
32. Rastan A., Brechtel K., Krankenberg H., et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J. Am. Coll. Cardiol. Aug 14 2012, 60(7):587-591.
33. Schmidt A., Piorkowski M., Werner M., et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J. Am. Coll. Cardiol. Sep 6 2011, 58(11):1105-1109.
34. Liistro F., Porto I., Angioli P., et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation Aug 2013, 128(6):615-621.
35. (Accessed April 11th, 2014). http://www.cxvascular.com/vn-latest-news/vascular-news--latest-news/inpact-amphirion-drug-eluting-balloon-trial-fails-to-meet-efficacy-endpoints-below-the-knee.
36. Duda S.H., Pusich B., Richter G., et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation Sep 17 2002, 106(12):1505-1509.
37. Duda S.H., Bosiers M., Lammer J., et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J. Endovasc. Ther. Dec 2006, 13(6):701-710.
38. Lammer J., Bosiers M., Zeller T., et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J. Vasc. Surg. Aug 2011, 54(2):394-401.
39. Dake M.D., Scheinert D., Tepe G., et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J. Endovasc. Ther. Oct 2011, 18(5):613-623.
40. Dake M.D., Ansel G.M., Jaff M.R., et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ. Cardiovasc. Interv. Oct 1 2011, 4(5):495-504.
41. Dake M.D., Ansel G.M., Jaff M.R., et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J. Am. Coll. Cardiol. Jun 18 2013, 61(24):2417-2427.
42. Scheinert D. Early Insights from the ESPRIT Study (Accessed June 20th, 2013). http://www.leipzig-interventional-course.com/index.php?option=com_docman&task=doc_download&gid=1326.
43. Wong A., Chan C. Drug-eluting stents: the end of restenosis?. Ann. Acad. Med. Singapore Jul 2004, 33(4):423-431.
44. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation Jan 7 2003, 107(1):38-42.
45. Tepe G., Zeller T., Albrecht T., et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. Feb 14 2008, 358(7):689-699.
46. Werk M., Langner S., Reinkensmeier B., et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation Sep 23 2008, 118(13):1358-1365.
47. Scheinert D. The Relevance of Optimal Coating for Successful DEB Technology-Lutonix Drug Coated Balloon Clinical Program 2013.
48. Scheinert D. Biolux P-I 12Months Data-In Practice 2013.
49. Werk M., Albrecht T., Meyer D.R., et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ. Cardiovasc. Interv. Dec 2012, 5(6):831-840.